Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10229011 | 0.82 | KMT2A (0.47) | KMT2AHPGDADORA3TRPV1TSHR | |
| SCHEMBL16047247 | 0.82 | KMT2A (0.52) | KMT2AHPGDCA2POLBTDP1 | |
| SCHEMBL19391819 | 0.81 | KMT2A (0.42) | KMT2AHPGDPOLBTDP1TSHR | |
| SCHEMBL8932275 | 0.81 | GPR139 (0.47) | KMT2ATDP1TSHRLMNAGPR139 | |
| SCHEMBL19391969 | 0.81 | GPR139 (0.43) | KMT2AHPGDTDP1TSHRLMNA | |
| SCHEMBL12026008 | 0.81 | KMT2A (0.43) | KMT2AAKT1POLBTDP1TSHR | |
| SCHEMBL6662585 | 0.80 | PKM (0.53) | HPGDTDP1LMNAHDAC3HDAC4 | |
| SCHEMBL7605014 | 0.79 | LMNA (0.49) | KMT2APOLBTDP1TSHRLMNA | |
| SCHEMBL18243806 | 0.79 | AKT1 (0.50) | KMT2AAKT1POLBTSHRLMNA | |
| SCHEMBL6057351 | 0.79 | KMT2A (0.50) | KMT2AHPGDTDP1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622572-B1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170342416-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2017-11-30 | — | — | US | disclosed |
| US-20170298355-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2017-10-19 | — | — | US | disclosed |
| EP-3231445-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170283816-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| EP-3222294-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9771588-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9738899-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9732344-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170211083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2017-07-27 | — | — | US | disclosed |
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090023675-A1 | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080039414-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIMA THERAPEUTICS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070167393-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-7205399-B1 | Methods and reagents for oligonucleotide synthesis | SIRNA THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070032441-A1 | treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070004663-A1 | each purine nucleotide is in said siNA is a 2' O-methyl purine nucleotide or each pyrimidine nucleotide in said siNA is a 2'-deoxy-2'-fluoro pyrimidine nucleotide; antisense agents against viral diseases | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004667-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004664-A1 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004665-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283816-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | KMT2A 285/4885HPGD 3402/4885AKT1 3649/4885 |
| US-20070004663-A1 | each purine nucleotide is in said siNA is a 2' O-methyl purine nucleotide or each pyrimidine nucleotide in said siNA is a 2'-deoxy-2'-fluoro pyrimidine nucleotide; antisense agents against viral diseases | ADAR, NSUN2, SNRPF | KMT2A 553/4885HPGD 3273/4885AKT1 3442/4885 |
| US-20090023675-A1 | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) | AGO2, SNRPE, SRRT | KMT2A 285/4885HPGD 3402/4885AKT1 3649/4885 |
| US-20070032441-A1 | treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | BRCA1, SNRPE, MITF | KMT2A 400/4885HPGD 2544/4885AKT1 4696/4885 |
| US-20070004664-A1 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | KMT2A 285/4885HPGD 3402/4885AKT1 3649/4885 |
| US-20170211083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | KMT2A 285/4885HPGD 3402/4885AKT1 3649/4885 |
| US-20070004665-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | KMT2A 414/4885HPGD 3127/4885AKT1 4600/4885 |
| US-20080039414-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | KMT2A 414/4885HPGD 3127/4885AKT1 4600/4885 |
| US-20070004667-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | KMT2A 414/4885HPGD 3127/4885AKT1 4600/4885 |
| US-20070167393-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | KMT2A 414/4885HPGD 3127/4885AKT1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.